Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
نویسندگان
چکیده
منابع مشابه
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
BACKGROUND In an earlier study, intravenous (i.v.) ibandronate 6 mg administered every 3-4 weeks had a similarly good renal safety profile whether infused over 15 or 60 min in women with breast cancer and bone metastases. This current study focuses on the renal safety of the extended use of ibandronate. PATIENTS AND METHODS Patients completing the original study could choose to enter a follow...
متن کاملRenal safety of ibandronate.
Despite their efficacy in treating complications associated with metastatic bone disease, there are concerns about the potential nephrotoxicity of certain i.v. bisphosphonates for the long-term management of cancer patients. Clinical data suggest, however, that i.v. ibandronate (Bondronat); F. Hoffman-La Roche Ltd., Basel, Switzerland, http://www.roche.com), unlike other bisphosphonates, has a ...
متن کاملLong-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
Several second-generation bisphosphonates (BPs) are approved in osteoporosis treatment. Efficacy and safety depends on potency of farnesyl pyrophosphate synthase (FPPS) inhibition, hydroxyapatite affinity, compliance and adherence. The latter may be influenced by frequency and route of administration. A literature search using "ibandronate", "postmenopausal osteoporosis", "fracture", and "bone ...
متن کاملLong term effects of a single dose of intravenous Ibandronate.
For defining the optimal regimen of a treatment of osteoporosis with an intravenous bisphosphonate one needs to know the duration of action of a single dose of the given drug. This allows us to establish the frequency by which a given dose has to be administered for obtaining a sufficient suppression of bone resorption over a longer period. In this study 1 and 2 mg Ibandronate were given as a s...
متن کاملLong-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
BACKGROUND Metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib typically survive >2 yr, with chronic treatment sometimes extending to ≥6 yr. OBJECTIVE To analyze long-term safety with sunitinib in mRCC patients. DESIGN, SETTING, AND PARTICIPANTS Data were pooled from 5739 patients in nine trials, comprising seven phase II studies, a phase III study, and an expande...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone
سال: 2010
ISSN: 8756-3282
DOI: 10.1016/j.bone.2010.01.081